Overview
The ATCvet QI category covers immunologicals (vaccines). Within the EMA Union Product Database (medicines-output-medicines-report, dataset generated 20/07/2026), the QI-classified pet medicines target cats (felidae), dogs (canidae), and horses (equidae). This entry documents the feline, canine, and equine vaccines in the database, covering core pathogens including FeLV, FHV, FCV, FPL, FCoV, canine babesiosis, and equine herpesvirus.
Feline Vaccines (QI06AX / QI06AH — Immunologicals for Felidae)
Nobivac NXT HCPChFeLV — EMEA/V/C/006520
- ATCvet code: (not recorded)
- INN: Feline calicivirosis, feline rhinotracheitis, feline panleucopenia, feline chlamydiosis (live) and feline leukemia (self-amplifying RNA particle) vaccine
- Active substance: Feline herpesvirus 1 (FHV), strain G2620A, live; Feline calicivirus (FCV), strain F9, live; Feline panleucopenia virus (FPL), strain MW-1, live; *Chlamydia felis*, strain Baker, live; Feline leukemia virus (FeLV) self-amplifying RNA (saRNA)-particle
- Species: Cats
- Status: Opinion
- Pharmacotherapeutic group: Immunologicals for felidae
- Marketing authorisation holder: Intervet International BV
Nobivac NXT HCPFeLV — EMEA/V/C/006682
- ATCvet code: QI06AX
- INN: Feline calicivirosis, feline rhinotracheitis, feline panleucopenia and feline leukemia (self-amplifying RNA particle) vaccine
- Active substance: Feline herpesvirus 1 (FHV), strain G2620A, live; Feline calicivirus (FCV), strain F9, live; Feline panleucopenia virus (FPL), strain MW-1, live; Feline leukemia virus (FeLV) self-amplifying RNA (saRNA)-particle
- Species: Cats
- Status: Opinion
- Pharmacotherapeutic group: Immunologicals for felidae
- Marketing authorisation holder: Intervet International B.V.
Nobivac NXT FeLV — EMEA/V/C/006683
- ATCvet code: QI06AX
- INN: Feline leukemia (self-amplifying RNA particle) vaccine
- Active substance: Feline leukemia virus (FeLV) self-amplifying RNA (saRNA)-particle: 10^6.6 – 10^9.3 RP (relative potency)
- Species: Cats
- Status: Opinion
- Pharmacotherapeutic group: Immunologicals for felidae
- Marketing authorisation holder: Intervet International B.V.
Purevax RCCh — EMEA/V/C/000092
- ATCvet code: QI06AH
- INN: Vaccine against feline viral rhinotracheitis, feline calicivirosis and feline Chlamydophila infections
- Active substance: Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain); inactivated feline calicivirosis antigen; inactivated *Chlamydophila felis* antigen
- Species: Cats
- Status: Lapsed
- Pharmacotherapeutic group: Immunologicals for felidae
- Therapeutic indication: Active immunisation of cats aged 8 weeks and older: against feline viral rhinotracheitis to reduce clinical signs; against feline calicivirosis to reduce clinical signs; against *Chlamydophila felis* infection to reduce clinical signs
- Marketing authorisation holder: Merial
Eurifel RCP FeLV — EMEA/V/C/000067
- ATCvet code: QI06AH
- INN: Vaccine against feline viral rhinotracheitis, calicivirosis, panleucopenia and leukaemia in cats
- Active substance: Canarypox virus expressing feline leukemia virus, live; Feline calicivirus, strain 255, inactivated; Feline herpesvirus 1, strain F2, live; Feline panleucopenia virus, strain 193E, inactivated
- Species: Cats
- Status: Withdrawn
- Pharmacotherapeutic group: Immunologicals for felidae
- Marketing authorisation holder: Merial
Canine Vaccines (QI07AO — Immunologicals for Canidae)
CaniLeish — EMEA/V/C/002232
- ATCvet code: QI07AO
- INN: Leishmania infantum excreted secreted proteins
- Active substance: *Leishmania infantum* excreted secreted proteins
- Species: Dogs
- Status: Withdrawn
- Pharmacotherapeutic group: Immunologicals
- Therapeutic indication: For the active immunisation of *Leishmania*-negative dogs from six months of age to reduce the risk to develop an active infection with *Leishmania infantum*
- Marketing authorisation holder: Virbac S.A.
Nobivac Piro — EMEA/V/C/000084
- ATCvet code: QI07AO
- INN: Vaccine against babesiosis in dogs
- Active substance: *Babesia canis*, inactivated; *Babesia rossi*, inactivated
- Species: Dogs
- Status: Withdrawn
- Pharmacotherapeutic group: Immunologicals for canidae
- Therapeutic indication: For active immunisation of dogs of six months of age or older against *Babesia canis* to reduce the severity of clinical signs of babesiosis
- Marketing authorisation holder: Intervet International BV
Equine Vaccines (QI05AA05 — Immunologicals for Equidae)
Equilis EHV 1+4 — EMEA/V/C/006147
- ATCvet code: QI05AA05
- INN: Equine herpesvirus vaccine (inactivated)
- Active substance: Equine herpesvirus 1, strain RAC-H; Equine herpesvirus 4, strain 2252
- Species: Horses
- Status: Application withdrawn
- Pharmacotherapeutic group: (not recorded in dataset)
- Marketing authorisation holder: Intervet International BV
Key Facts
- Nobivac NXT series (EMEA/V/C/006520, /006682, /006683) — three feline vaccines under Opinion status, incorporating self-amplifying RNA (saRNA) technology for FeLV; novel platform for EMA veterinary authorisations.
- FeLV (feline leukemia virus) vaccines appear in multiple products (Nobivac NXT HCPChFeLV, Nobivac NXT HCPFeLV, Nobivac NXT FeLV, Eurifel RCP FeLV) — indicating ongoing MA activity for feline leukaemia prevention.
- CaniLeish (QI07AO) — *Leishmania infantum* excreted secreted proteins vaccine for dogs; active immunisation of *Leishmania*-negative dogs from 6 months of age; holder Virbac S.A.; Withdrawn.
- Nobivac Piro (QI07AO) — *Babesia canis* and *B. rossi* inactivated vaccine for canine babesiosis; Intervet International BV; Withdrawn.
- Equilis EHV 1+4 (QI05AA05) — equine herpesvirus 1 and 4 bivalent inactivated vaccine for horses; Intervet International BV; Application withdrawn.
Source: EMA medicines-output-medicines-report_en.xlsx, dataset generated 20/07/2026 - 18:00, accessed via https://www.ema.europa.eu/en/medicines/download-medicine-data.